Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Haleon (LON:HLN) Stock Price

Haleon (LON:HLN) had its price target boosted by Deutsche Bank Aktiengesellschaft from GBX 325 to GBX 335 in a research report released on Friday morning,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a sell rating on the stock.

Several other research firms also recently commented on HLN. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 370 price objective on shares of Haleon in a report on Thursday, April 30th. Berenberg Bank restated a “buy” rating and set a GBX 512 target price on shares of Haleon in a research note on Thursday, April 30th. JPMorgan Chase & Co. cut their target price on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research note on Thursday, June 25th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 400 target price on shares of Haleon in a report on Friday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Haleon presently has an average rating of “Hold” and a consensus price target of GBX 395.33.

Haleon Stock Down 1.4%

HLN stock opened at GBX 363.30 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The firm has a market capitalization of £32.00 billion, a PE ratio of 19.64, a PEG ratio of 1.49 and a beta of 0.24. Haleon has a 1-year low of GBX 317.80 and a 1-year high of GBX 416.10. The business’s 50 day simple moving average is GBX 349.84 and its 200 day simple moving average is GBX 363.11.

Haleon (LON:HLN) last posted its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a return on equity of 10.30% and a net margin of 15.11%. As a group, research analysts anticipate that Haleon will post 19.5033282 EPS for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.